Kala Pharmaceuticals, Inc. (KALA), is about to release some big news that will move this little company in a big way. This little company should have a place in your portfolio. I will highlight the important information needed to get you up to speed to make an informed trade.
Source: Kalarx.com
My focus is on highlighting high quality companies that are undervalued. The company debuted as an IPO on July 20, 2017. My first recommendation on KALA was on Oct 26, 2017. Within weeks, the stock had rallied 42.76%. The stock has since slipped back to an attractive level.
Kala Pharmaceuticals is a late stage biopharmaceutical company focused on developing and commercializing nanoparticle-based Mucus Penetrating Particles or MPP. The company has opted to pursue ocular indications in early development but the technology could have wider application in other organ systems. The two advanced candidates are INVELTYS (KPI-121 1%), and KPI-121 0.25%.
